OrbiMed Boosts RAPT Therapeutics Stake Ahead of $58 Per Share Acquisition

Key Facts

1OrbiMed Advisors increased its position in RAPT Therapeutics by 556,273 shares during the fourth quarter.

2RAPT Therapeutics was acquired for $58 per share.

3OrbiMed's stake in the company was valued at approximately $56 million prior to the acquisition.

OrbiMed Advisors significantly increased its position in RAPT Therapeutics during the fourth quarter, according to recent financial reports. The healthcare-focused investment firm added 556,273 shares to its holdings just before the company was acquired. RAPT Therapeutics was subsequently acquired at a price of $58 per share, offering a guaranteed valuation and exit for existing shareholders. Prior to the acquisition, OrbiMed's total stake in the biotechnology firm was valued at approximately $56 million. This institutional accumulation highlights a strategic move by institutional investors ahead of a major corporate event. The acquisition at a premium validates the investment thesis and underscores the ongoing consolidation activity within the biotech sector.